Phase I dose-escalation study evaluating safety, tolerability and pharmacokinetics of MEDI-573, a dual IGF-I/II neutralizing antibody, in Japanese patients with advanced solid tumours
Crossref DOI link: https://doi.org/10.1007/s10637-014-0170-x
Published Online: 2014-10-25
Published Print: 2015-02
Update policy: https://doi.org/10.1007/springer_crossmark_policy
Iguchi, Haruo
Nishina, Tomohiro
Nogami, Naoyuki
Kozuki, Toshiyuki
Yamagiwa, Yumiko
Yagawa, Katsuro
Text and Data Mining valid from 2014-10-25
Version of Record valid from 2014-10-25
Article History
Received: 8 July 2014
Accepted: 2 October 2014
First Online: 25 October 2014